HC Wainwright Has Optimistic Outlook of RARE Q1 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at HC Wainwright raised their Q1 2026 earnings per share estimates for Ultragenyx Pharmaceutical in a report issued on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($1.55) per share for the quarter, up from their prior estimate of ($1.63). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($4.05) EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $1.19 EPS, Q3 2027 earnings at $1.55 EPS, Q4 2027 earnings at $2.64 EPS and FY2027 earnings at $5.66 EPS.

RARE has been the topic of a number of other research reports. Jefferies Financial Group lowered their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday, December 30th. Leerink Partners dropped their price objective on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Barclays reduced their target price on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th. Canaccord Genuity Group lowered their price target on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Wedbush reiterated a “neutral” rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $68.29.

Ultragenyx Pharmaceutical Stock Up 6.7%

Shares of Ultragenyx Pharmaceutical stock opened at $21.83 on Thursday. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -3.74 and a beta of 0.16. Ultragenyx Pharmaceutical has a 52-week low of $18.41 and a 52-week high of $45.00. The company’s 50-day simple moving average is $25.67 and its 200-day simple moving average is $29.54.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 566.58%. The firm had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. During the same period in the prior year, the firm posted ($1.39) earnings per share. The business’s quarterly revenue was up 25.5% compared to the same quarter last year.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Assetmark Inc. boosted its holdings in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares during the period. Huntington National Bank lifted its position in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the last quarter. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $39,000. Smartleaf Asset Management LLC grew its holdings in Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,169 shares during the last quarter. Finally, Covestor Ltd increased its position in Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 369 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Howard Horn sold 3,061 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the sale, the chief financial officer owned 88,935 shares in the company, valued at approximately $2,095,308.60. This represents a 3.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 6,227 shares of company stock valued at $187,126 over the last ninety days. Insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright raised multiple 2026–2027 EPS forecasts, lifted several quarterly estimates and reiterated a Buy rating with a $50 price target — a bullish research view that supports potential upside if clinical/commercial execution meets their forecast. HC Wainwright coverage
• Neutral Sentiment: Canaccord cut its price target from $128 to $79 but kept a Buy rating; the lowered target reduces the analyst-implied upside even though the stance remains constructive. Canaccord note
• Neutral Sentiment: Wedbush reiterated a Neutral rating on RARE, providing little near‑term catalyst from that shop. Wedbush note
• Negative Sentiment: Multiple plaintiffs’ law firms have filed or are soliciting class members in a securities‑fraud suit (class period alleged: Aug 3, 2023–Dec 26, 2025) and are reminding investors of an April 6, 2026 lead‑plaintiff deadline. The filings allege material misstatements/omissions tied to setrusumab and create legal and settlement risk — a clear overhang that can pressure the stock while the case progresses. Representative notices: Pomerantz (PR Newswire), Robbins Geller (PR Newswire), Levi & Korsinsky (GlobeNewsWire). Pomerantz notice Robbins Geller notice Levi & Korsinsky notice

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.